1. Home
  2. CSTL vs FTH Comparison

CSTL vs FTH Comparison

Compare CSTL & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$35.08

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

N/A

Current Price

$19.84

Market Cap

835.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
FTH
Founded
2007
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
835.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CSTL
FTH
Price
$35.08
$19.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
15
Target Price
$46.70
★ $55.38
AVG Volume (30 Days)
323.1K
★ 357.9K
Earning Date
11-05-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $344,229,000.00
N/A
Revenue This Year
$8.68
N/A
Revenue Next Year
$12.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.66
N/A
52 Week Low
$17.72
$16.57
52 Week High
$44.28
$42.14

Technical Indicators

Market Signals
Indicator
CSTL
FTH
Relative Strength Index (RSI) 52.00 40.10
Support Level $33.90 $16.57
Resistance Level $37.42 $21.97
Average True Range (ATR) 1.76 2.09
MACD 0.23 0.39
Stochastic Oscillator 47.06 60.74

Price Performance

Historical Comparison
CSTL
FTH

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

Share on Social Networks: